Home Cart Sign in  
Chemical Structure| 2828433-17-4 Chemical Structure| 2828433-17-4

Structure of 2828433-17-4

Chemical Structure| 2828433-17-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LSKL is a peptide derived from LAP-TGFβ that competitively inhibits TGF-β1 activity, alleviating liver fibrosis and renal interstitial fibrosis, and can cross the blood-brain barrier to inhibit subarachnoid fibrosis, preventing chronic hydrocephalus and improving neurocognitive deficits after subarachnoid hemorrhage, suitable for research on various fibrotic diseases.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)

CAS No. :2828433-17-4
Formula : C23H43F3N6O7
M.W : 572.62
SMILES Code : O=C(N[C@@H](CC(C)C)C(N)=O)[C@@H](NC([C@@H](NC([C@@H](N)CC(C)C)=O)CO)=O)CCCCN.O=C(O)C(F)(F)F
MDL No. :N/A

Safety of LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.75mL

0.35mL

0.17mL

8.73mL

1.75mL

0.87mL

17.46mL

3.49mL

1.75mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories